The stock of Opko Health (NASDAQ: OPK) didn't have its healthiest day on Friday, falling by 7.8% in the wake of the company's latest earnings report. For its second quarter, Opko Health posted $442.4 million in revenue, nearly 47% higher on a year-over-year basis. Largely on the basis of those testing products, however, analysts were collectively expecting nearly $456.4 million on the top line.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting